Abstract
The landmark paper discussed in this chapter is ‘Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain’, published by Ranoux et al. in 2008. The muscle-relaxant properties of botulinum toxin type A (BTX-A) have long been known and used therapeutically. However, BTX-A actions independent of those affecting neuromuscular function had previously only been alluded to, via the observation that BTX-A injections alleviated pain more than would have been expected through the treatment of muscle spasm alone. This paper was one of the first to specifically examine the efficacy of BTX-A in neuropathic pain and was a catalyst for further investigation into BTX-A as a novel analgesic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
